$RNAZ
Transcode Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Boston, MA
RNAZ chart
What traders are saying about $RNAZ
Latest postsTranscode Therapeutics, Inc. news
- TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
Yahoo Finance ·
- TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
Yahoo Finance ·
- Natera Partners With TransCode to Advance Colorectal Cancer Trial
Yahoo Finance ·
- TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
Yahoo Finance ·
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Yahoo Finance ·
- TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
Yahoo Finance ·
- TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
Yahoo Finance ·
- Join Today's Live Investor Webinar with TransCode Therapeutics
Yahoo Finance ·
- TransCode Therapeutics Announces Leadership Transition
Yahoo Finance ·
- Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer
Yahoo Finance ·
- TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
Yahoo Finance ·
- Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
Yahoo Finance ·
Transcode Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$34.7M | -$16.8M | -$18.5M | -$17.6M |
| Diluted EPS | $-52.59 | $-1336.63 | $-3419.01 | $-1082.79 |
| Total assets (year end) | $162.4M | $7.3M | $5.2M | $7.6M |
| Cash and equivalents (year end) | $17.8M | $5.8M | $2.8M | $5.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Transcode Therapeutics, Inc.
- Ticker
- RNAZ (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1829635
Frequently asked questions
What exchange is Transcode Therapeutics, Inc. listed on?
Transcode Therapeutics, Inc. trades on the Nasdaq under the ticker symbol RNAZ.
What industry is Transcode Therapeutics, Inc. in?
Transcode Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Transcode Therapeutics, Inc. headquartered?
Transcode Therapeutics, Inc.'s business address on file with the SEC is in Boston, MA.
When does Transcode Therapeutics, Inc.'s fiscal year end?
Transcode Therapeutics, Inc.'s fiscal year ends on December 31.